Referências

1. Latour RP, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024 Mar 14;390(11):994-1008. 2. Fishman J, Kuranz S, Yeh MM, Brzozowski K, Chen H. Changes in Hematologic Lab Measures Observedin Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network. Hematol Rep. 2023 Apr 21;15(2):266-282. 3. Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022 Feb;101(2):251-263. 4. Debureaux PE, Kulasekararaj AG, Cacace F, Silva BGP, Calado RT, Barone F, et al. Severe Aplastic Anemia Working Party of the European Group for Bone Marrow Transplantation. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. 5. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017 May 18;3:17028. 6. Risitano AM, Frieri C, Marano L, Urciuoli E, Sanseverino A, Nannelli C, et al. Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complemente inhibitor to anti-C5 therapy: A lesson not to be forgotten. Am J Hematol. 2024 Oct 12.